Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine

Chinese Clinical Oncology

Volumn 3, Issue 2, 2014, Pages

  Mandrekar, Sumithra J ^a   Sargent, Daniel J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adaptive design; All comers design; Biomarker; Enrichment design; Hybrid design; Randomized controlled trial (RCT)

Indexed keywords

EID: 84926014085     PISSN: 23043865     EISSN: 23043873     Source Type: Journal    
DOI: 10.3978/j.issn.2304-3865.2014.05.03     Document Type: Review

References (55)

1. Hammond ME, Taube SE. Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. Semin Oncol 2002;29:213-21.
2. Sargent DJ, Mandrekar SJ. Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers. Clin Trials 2013;10:647-52.
3. Mandrekar SJ, Sargent DJ. Clinical Trial Designs for Biomarker Evaluation. Personalized Medicine in Oncology, Vol 1, No 1-Biomarkers, May 2012.
4. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009;27:4027-34.
5. Prentice, RL. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 1989;8:431-40.
6. Buyse M, Sargent DJ, Grothey A, et al. Biomarkers and surrogate end points--the challenge of statistical validation. Nat Rev Clin Oncol 2010;7:309-17.
7. Simon RM, Paik S, Hayes DF. Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. J Nat Cancer Inst 2009;101:1446-52.
8. Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100.
9. Zhou X, Liu S, Kim ES. Bayesian adaptive design for targeted therapy development in lung cancer-a step towards personalized medicine. Clinical Trials 2008;5:181-93.
10. Simon R, Wang SJ. Use of genomic signatures in therapeutics development in oncology and other diseases. Pharmacogenomics J 2006;6:166-73.
11. Jiang W, Freidlin B, Simon R. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst 2007;99:1036-43.
12. Freidlin B, Jiang W, Simon R. The Cross-Validated Adaptive Signature Design. Clin Cancer Res 2010;16:691-8.
13. Mandrekar SJ, Qin R, Sargent DJ. Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: methods and challenges. Stat Med 2010;29:1077-83.
14. Storer BE. Choosing a Phase I Design. In Handbook of Statistics in Clinical Oncology. Crowley J, Hoering A. eds. Chapman & Hall/CRC: Boca Raton, FL, 2012:3-20.
15. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: A practical design for Phase 1 clinical trials in cancer. Biometrics 1990;46:33-48.
16. Braun TM. The bivariate continual reassessment method. extending the CRM to phase I trials of two competing outcomes. Control Clin Trials 2002;23:240-56.
17. Thall PF, Cook JD. Dose-finding Based on Efficacy-Toxicity Trade-offs. Biometrics 2004;60:684-93.
18. Yin G, Li Y, Ji Y. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios. Biometrics 2006;62:777-84.
19. Bekele BN, Shen Y. A Bayesian Approach to Jointly Modeling Toxicity and Biomarker Expression in a Phase I/II Dose-finding Trial. Biometrics 2005;61:343-54.
20. Dragalin V, Fedorov V. Adaptive designs for dose-finding based on efficacy-toxicity response. J Stat Plan Inference 2006;136:1800-23.
21. Thall PF, Russell KE. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics 1998;54:251-64.
22. Zhang W, Sargent DJ, Mandrekar SJ. An adaptive dose-finding design incorporating both toxicity and efficacy. Stat Med 2006;25:2365-83.
23. Mandrekar SJ, Cui Y, Sargent DJ. An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations. Stat Med 2007;26:2317-30.
24. Zohar S, Chevret S. Recent developments in adaptive designs for Phase I/II dose-finding studies. J Biopharm Stat 2007;17:1071-83.
25. Mandrekar SJ. Dose-finding trial designs for combination therapies in oncology. J Clin Oncol 2014;32:65-7.
26. Manji A, Brana I, Amir E, et al. Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. J Clin Oncol 2013;31:4260-7.
27. Chapman PB, Hauschild A, Robert C, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med 2011;364:2507-16.
28. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
29. Pusztai L, Anderson K, Hess KR. Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. Clin Cancer Res 2007;13:6080-6.
30. Tang H, Foster NR, Grothey A, et al. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol 2010;28:1936-41.
31. McShane LM, Hunsberger S, Adjei AA. Effective incorporation of biomarkers into phase II trials. Clin Cancer Res 2009;15:1898-905.
32. Mandrekar SJ, An MW, Sargent DJ. A review of phase II trial designs for initial marker validation. Contemp Clin Trials 2013;36:597-604.
33. Shi Q, Mandrekar SJ, Sargent DJ. Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials. Scand J Gastroenterol 2012;47:356-62.
34. Berry DA. Adaptive clinical trials: the promise and the caution. J Clin Oncol 2011;29:606-9.
35. Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100.
36. Zhou X, Liu S, Kim ES. Bayesian adaptive design for targeted therapy development in lung cancer-a step towards personalized medicine. Clinical Trials 2008;5:181-93.
37. An MW, Mandrekar SJ, Sargent DJ. A 2-Stage Phase II Design with Direct Assignment Option in Stage II for Initial Marker Validation. Clin Cancer Res 2012;18:4225-33.
38. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8.
39. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
40. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
41. Wang SJ, O'Neill RT, Hung HM. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat 2007;6:227-44.
42. Liu A, Liu C, Li Q, et al. A threshold sample-enrichment approach in a clinical trial with heterogeneous subpopulations. Clin Trials 2010;7:537-45.
43. Simon R, Wang SJ. Use of genomic signatures in therapeutics development in oncology and other diseases. Pharmacogenomics J 2006;6:166-73.
44. Bauer P. Multiple testing in clinical trials. Stat Med 1991;10:871-89; discussion 889-90.
45. Song Y, Chi GY. A method for testing a prespecified subgroup in clinical trials. Stat Med 2007;26:3535-49.
46. Freidlin B, Korn EL, Gray R. Marker Sequential Test (MaST) design. Clin Trials 2014;11:19-27.
47. Jiang W, Freidlin B, Simon R. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst 2007;99:1036-43.
48. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 2005;11:7872-8.
49. Freidlin B, Jiang W, Simon R. The Cross-Validated Adaptive Signature Design. Clin Cancer Res 2010;16:691-8.
50. Hunsberger S, Zhao Y, Simon R. A comparison of phase II study strategies. Clin Cancer Res 2009;15:5950-5.
51. Parmar MK, Barthel FM, Sydes M, et al. Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst 2008;100:1204-14.
52. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53.
53. Redman MW, Crowley JJ, Herbst RS, et al. Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. Clin Cancer Res 2012;18:4004-12.
54. Farina G, Longo F, Martelli O, et al. Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations. Clin Lung Cancer 2011;12:138-41.
55. Rosell R, Taron M, Sanchez JJ, et al. Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. Future Oncol 2007;3:277-83.